Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine

• Anti-diphtheria, anti-tetanus, anti-PT, anti-FHA, anti-PRN and anti-poliovirus type 1, 2 and 3 antibody concentrations/titres [ Time Frame: Prior to and one month after booster vaccination. ] [ Designated as safety issue: No ]
• Booster response to the PT, FHA and PRN antigens [ Time Frame: One month after booster vaccination. ] [ Designated as safety issue: No ]
• Occurrence of solicited local and general symptoms [ Time Frame: During the 4-day follow-up period after booster vaccination ] [ Designated as safety issue: Yes ]
• Occurrence of unsolicited symptoms [ Time Frame: During the 31-day follow-up period after booster vaccination ] [ Designated as safety issue: Yes ]
• Occurrence of SAEs [ Time Frame: Following booster vaccination ] [ Designated as safety issue: Yes ]

• Anti-diphtheria, anti-tetanus, anti-PT, anti-FHA, anti-PRN and anti-poliovirus type 1, 2 and 3 antibody concentrations/titres [ Time Frame: Prior to and one month after booster vaccination. ]
• Booster response to the PT, FHA and PRN antigens [ Time Frame: One month after booster vaccination. ]
• Occurrence of solicited local and general symptoms [ Time Frame: During the 4-day follow-up period after booster vaccination ]
• Occurrence of unsolicited symptoms [ Time Frame: During the 31-day follow-up period after booster vaccination ]
• Occurrence of SAEs [ Time Frame: Following booster vaccination ]

Subjects aged 9 to 13 years who participated in the 711866/001 study 5 years ago will be evaluated for immune persistence and will receive a combined dTpa-IPV booster dose that will be evaluated in terms of immunogenicity, safety and reactogenicity.

• Poliomyelitis
• Diphtheria
• Pertussis
• Tetanus

• Experimental: Group A
  Intervention: Biological: Boostrix-Polio
• Experimental: Group B
  Intervention: Biological: Boostrix-Polio

Inclusion Criteria:

• Subjects who the investigator believes that they or their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
• A male or female subject who received a booster vaccination with dTpa-IPV or dTpa + IPV in study 711866/001.
• Healthy subjects as established by medical history and clinical examination before entering into the study.
• Females of childbearing potential at the time of study entry must have a negative pregnancy test prior to administration of the dose of vaccine and are required to be abstinent or to use adequate contraceptive precautions for one month prior to vaccination. Subjects are required to agree to continue such precautions for two months after vaccination.
• Written informed consent obtained from both parents/ guardians of the subject; assent from the subject himself/herself should also be requested whenever possible.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
• Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs within six months prior to the booster dose.
• Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during study period.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
• Previous booster vaccination against tetanus, diphtheria, pertussis, or poliomyelitis since the booster dose received in study 711866/001.
• History of diphtheria, tetanus, pertussis, or poliomyelitis diseases.
• Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• Administration of immunoglobulin and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
• Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
• Occurrence of any of the following adverse events (AEs) after a previous administration of a DTP vaccine: hypersensitivity reaction to any component of the vaccine, encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine, fever ≥ 40°C within 48 hours of vaccination not due to another identifiable cause, collapse or shock-like state within 48 hours of vaccination
• Persistent, severe, inconsolable screaming or crying lasting >3 hours occurring within 48 hours of receipt of a previous dose of DTP vaccine convulsions with or without fever, occurring within 3 days of vaccination.
• Acute disease at the time of enrolment.
• Pregnant or lactating female.